Clinical Trial Update: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing HX008 plus irinotecan to placebo plus irinotecan as second-line treatment for advanced gastric cancer is ongoing (status UNKNOWN).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stomach Cancer

Drugs mentioned

• HX008 + irinotecan
• Irinotecan (Irinotecan)

Snippet

Sponsor: Taizhou Hanzhong biomedical co. LTD | Conditions: Stomach Cancer | Phase 3 | Status: UNKNOWN